AMGN : Analysis & Opinions

  • Showing 1-100 of 103 items
  • 1
  • 2
  • >>
  1. Laurel Grove Capital, LLC Buys AvalonBay Communities Inc, Accenture ...

    January 12, 2017
    Los Angeles, CA, based Investment company Laurel Grove Capital, LLC buys AvalonBay Communities Inc, Accenture PLC, Time Warner ...
  2. Daiwa SB Investments Ltd. Buys JM Smucker Co, Vanguard S&P 5 ...

    January 12, 2017
    Tokyo, M0, based Investment company Daiwa SB Investments Ltd. buys JM Smucker Co, Vanguard S&P 500, McDonald's Corp, ...
  3. Amgen Launches Cancer Partnership With Immatics

    January 9, 2017
    Amgen and Immatics launched a cancer-drug partnership that will combine immunology with oncology.
  4. Amgen Set to Test Two Year Range Resistance (AMGN)

    January 6, 2017
    Amgen has posted a 2-month bullish island reversal this week, setting the stage for its seventh assault on range resistance ...
  5. Regeneron, Sanofi Cholesterol Drug Gets Blocked

    January 6, 2017
    A US court barred Regeneron and Sanofi from selling their cholesterol drug due to patient issues.
  6. Biosimilar Drugs To Take On Top Brand Names

    January 4, 2017
    Makers of biosimilar drugs may erode the market share of top brand names as competition heats up.
  7. Amgen Keeps Cholesterol Drug Patent Vs Regeneron

    January 4, 2017
    A judge rejected an appeal by Regeneron and Sanofi to overturn Amgen's cholesterol-drug patent.
  8. Pharma M&A Boom Expected from 'Trump Tax Holiday'

    January 3, 2017
    Trump's proposed tax holiday may cause a boom in drug mergers, leading to potential job losses.
  9. Migraine Biologics Drugs Has Blockbuster Potential

    January 3, 2017
    Drug makers who launch migraine biologic drugs are expected to benefit from blockbuster sales.
  10. Amgen Rolls Out Kidney Disease Campaign (AMGN)

    December 5, 2016
    The BloodCounts campaign aims to provide moral support to patients and caregivers, along with sharing of vital information.
  11. Amgen, Allergan File for Avastin Biosimilar in EU (AGN)

    December 5, 2016
    Amgen and Allergan are all set to grab a slice of billion-dollar cancer drug market with their ABP 215 biosimilar.
  12. Allergan & Amgen Looking for Approvals (AGN, AMGN)

    December 2, 2016
    Amgen and Allergan file in to get approval for Avastin biosimilar ABP 215 in Europe.
  13. Cytokinetics Gets $27M Milestone from Amgen (AMGN, CYTK)

    December 1, 2016
    Cytokinetics and Amgen will launch a Phase 3 trial of their heart-failure drug after successful early-stage results.
  14. Arrowhead Halts 3 Drug Projects, Axes Jobs (ARWR)

    December 1, 2016
    Arrowhead suspended three drug programs following FDA holds on the failure of the company's EX1 drug delivery vehicle.
  15. Amgen Migraine Drug Does Well in Late Study (AMGN)

    November 17, 2016
    Amgen remains ahead of its competitors by being the first to publish positive late-stage study data for its migraine drug.
  16. Amgen Files BLA for Avastin Biosimilar (AMGN, AGN)

    November 16, 2016
    Amgen leaps ahead with its biosimilars program, adding an Avastin copycat to its portfolio.
  17. Soros 13F Points to More Than Just Emerging Markets

    November 15, 2016
    Soros Fund Management's 13F for Q3 indicates new positions in several energy comapnies, call options for Bank of America, ...
  18. Amgen's Parsabiv Kidney Drug Approved in EU (AMGN)

    November 14, 2016
    Amgen wins European approval for its Parsabiv drug to treat chronic kidney disease.
  19. Amgen, Janssen to Begin Myeloma Trial (AMGN, JNJ)

    November 11, 2016
    The companies will launch combination drug studies to treat multiple myeloma, or cancer of the plasma cells.
  20. Amgen's Enbrel Drug OKed for Pediatric Use (AMGN)

    November 9, 2016
    Amgen's Enbrel drug was approved to treat children with plaque psoriasis, expanding its scope beyond adult patients.
  21. Pfizer Scraps New Cholesterol Drug (PFE, AMGN)

    November 2, 2016
    Pfizer will take a 4-cent-a-share charge in its 4Q earnings after scrapping its new cholesterol drug.
  22. Pricey Cholesterol Drugs Lose Favor (AMGN, REGN)

    October 31, 2016
    Expensive new cholesterol drugs haven't been selling well, and that's worrying some major drug companies.
  23. Amgen Raises 4Q Earnings Projections (AMGN)

    October 28, 2016
    Amgen's 3Q earnings and revenue topped analyst estimates, thanks to cost-cutting measures.
  24. Amgen Tops Q3 Profit Projections (AMGN)

    October 28, 2016
    Aided by the decrease of expenses such as late state clinical trials, Amgen reported positive third-quarter earnings.
  25. Amgen Invests in Israeli Digital Health Co. (AMGN)

    October 26, 2016
    Amgen invested in an Israeli digital health incubator called eHealth Ventures.
  26. Zacks: Amgen To Surpass Q3 Expectations (AMGN)

    October 25, 2016
    Backed by solid product growth, Amgen will announce its third-quarter performance Thursday; Zacks says it will “beat expectations.” ...
  27. Amgen to Pay $1 Per Share 4Q Dividend (AMGN)

    October 17, 2016
    Amgen declared a 4Q dividend of $1 per share, and named Ellen J. Kullman a director, expanding its board to 14.
  28. Does a Clinton Victory Scare the Biotech Sector? (AMGN, ILMN)

    October 13, 2016
    Biotech stocks face further turmoil if the Democrats win control of Congress and move to rein in prices for new drugs
  29. Amgen Reports Positive Cancer Drug Results (AMGN)

    October 11, 2016
    The data show the potential of Amgen’s key drug, Vectibix, to emerge as an effective treatment for left-sided metastatic ...
  30. Amgen Set To Appear at ESMO Congress (AMGN)

    October 6, 2016
    Amgen is scheduled to appear at European Society for Medical Oncology 2016 Congress to present new data and research on IMLYGIC ...
  31. Amgen Inks Oncology, Neuroscience Deals (AMGN)

    October 5, 2016
    Aimed at enhancing its drug development, Amgen is joining hands with a Stockholm company to leverage its Chemetics platform
  32. Amgen Signs Agreement With Exosome Dignostics (AMGN)

    October 3, 2016
    The two companies will collaborate to discover a potential liquid biopsy diagnostic to advance Amgen’s drug development.
  33. Friends or Foes: Amgen and Novartis (AMGN, NVS)

    October 3, 2016
    While the two companies collaborate on developing drugs for migraine and Alzheimer’s disease, they are in a court battle ...
  34. Amgen Expands New Drugs Into Indian Market (AMGN, RDY)

    October 3, 2016
    The company is building on its existing alliance with Dr. Reddy’s Laboratories for marketing three new drugs in India.
  35. Amgen’s Kyprolis Fails in Trial (AMGN)

    September 29, 2016
    The failure in a comparative study has raised doubts about Amgen’s $10.4 billion takeover of the drug.
  36. Amgen’s Backup Plan for Kyprolis (AMGN)

    September 29, 2016
    Despite its recent failure, Amgen has a few options in place to resume kyprolis trials and move ahead with commercialization.
  37. Long Wait for Biosimilar Amjevita (AMGN)

    September 29, 2016
    While Amgen’s Humira biosimilar called Amjevita has been approved by the FDA, it will be a very long wait for real commercial ...
  38. Amgen Maintains Migraine Drug Lead (AMGN)

    September 29, 2016
    Amgen leads the migraine drug race by being the first company to publish phase 3 results, but intense competition looms in ...
  39. Amgen Arrowhead Announce Two Cardiovascular Collaborations (AMGN, ...

    September 29, 2016
    Partnership between the two firms focused on genetic discoveries and cardiovascular disease treatment offers a win-win
  40. Amgen Reports Positive Results for Trial (AMGN)

    September 28, 2016
    Positive top-line data from an ongoing high-resolution imaging trial reinstates a promising outlook for treating cardiovascular ...
  41. 3 Nasdaq-100 Stocks Ready to Play Catch-Up

    September 28, 2016
    These Nasdaq-100 components show stronger buying interest than price gains, predicting the price will play catch up in coming ...
  42. Amgen's Biosimilar Gets FDA Approval (AMGN, ABBV)

    September 27, 2016
    The company’s first biosimilar, Amjevita, is now approved for seven common inflammatory ailments and may encroach on AbbVie's ...
  43. Amgen's Osteoporosis Drug Crosses a Hurdle (AMGN)

    September 27, 2016
    Amgen’s osteoporosis drug moves one step ahead in the FDA approval process, and recent results show better performance than ...
  44. Amgen’s Venture Funding Initiative (AMGN)

    September 26, 2016
    The company known for developing human therapeutics is also funding biotech ventures through a partnership fund
  45. Amgen Sees Approval for Osteoporosis Drug (AMGN)

    September 20, 2016
    Amgen hopes that its osteoporosis drug, romosozumab, can win FDA approval by 2017 to target $1 billion in sales
  46. Amgen-Servier Collaboration Commercializes Chronic Heart Therapy ...

    September 19, 2016
    Amgen’s partnership wiTH France's Servier Laboratories for its chronic heart failure offers huge market potential.
  47. Amgen Products Threatened by Court Losses (AMGN)

    September 19, 2016
    Amgen's losses in lawsuits against Apobiologix's over two biosimilar products means the biotech giant may be vulnerable to ...
  48. AMGN: How Amgen's Stock Price Rose 18.55% in 6 Months

    September 17, 2016
    Amgen's stock price has outpaced biotechnology and health care ETFs over the past six months due to a solid product pipeline ...
  49. Amgen Targeting Biosimilars (AMGN)

    September 16, 2016
    Amid emerging biosimilar challenges, Amgen is taking the legal route to thwart and delay competition, in addition to pursuing ...
  50. Top 5 Health Care Stocks of 2016 (AMGN, BMY)

    August 25, 2016
    Discover why the baby boomers are benefiting the health care sector. Explore five health care stocks that are well positioned ...
  51. Long-term Upside Breakouts Close at Hand

    July 11, 2016
    These three stocks are approaching major highs and resistance, and a breakout could mean another strong advance to the upside.
  52. These Stocks Are Strong July Performers (AMGN, BPL)

    June 29, 2016
    These stocks tend to rally in July, moving higher approximately 80% of the time.
  53. Big Biotech Set to Bounce Off Deep Lows (GILD, CELG)

    June 23, 2016
    Relative strength indicators in the biotech sector have hit their deepest oversold readings since 2008, predicting a strong ...
  54. Samsung Moves to List Bioepis for $2.5B

    June 9, 2016
    With European approval for Flixabi, Samsung Bioepis appears all set for its awaited IPO.
  55. The Share Buyback Report: Health Care Sector (PFE, JNJ)

    June 3, 2016
    Analyze health care sector share repurchase data to identify trends. Determine which factors influence volume and which companies ...
  56. American Funds Investment Company Performance Case Study (AIVSX)

    May 4, 2016
    Learn more about American Funds Investment Company of America mutual fund including fund history, asset holding composition, ...
  57. American Funds AMCAP Fund Performance Case Study (AMCPX)

    April 29, 2016
    Explore the market-beating performance of the American Funds AMCAP Fund, including the seasonal patterns when buying and ...
  58. The 3 Largest Health Care ETFs (XLV, IBB)

    April 25, 2016
    Find out which exchange-traded funds (ETFs) are the largest in terms of total assets under management (AUM) in the health ...
  59. American Funds Capital Income Builder Trends in 2016 (CAIBX)

    April 15, 2016
    Learn about the composition of the American Funds Capital Income Builder fund, and discover how its makeup has evolved between ...
  60. (VHT) Vanguard Healthcare ETF: Top 5 Holdings

    March 19, 2016
    Identify the top five holdings in the Vanguard Health Care exchange-traded fund (ETF), and evaluate each holding's business ...
  61. 4 Defensive ETFs Worth Your While (VHT, PGX)

    March 19, 2016
    Find out which top exchange-traded funds (ETFs) would be well worth your consideration when deploying a defensive investment ...
  62. (IBB) iShares NASDAQ Biotech SPDR ETF: Top 5 Holdings

    March 16, 2016
    Take a close look at the strong fundamentals underlying the top five holdings of the iShares NASDAQBiotechnology ETF as it ...
  63. Analyzing Amgen's Debt Ratios in 2016 (AMGN)

    February 29, 2016
    Learn about Amgen Inc. and its key debt ratios, such as the debt-to-equity ratio, interest coverage ratio and cash flow-to-debt ...
  64. Amgen: An Activist Investment Analysis (AMGN)

    February 26, 2016
    Learn about the activist investor campaign Third Point Partners has initiated against Amgen. Read about Third Point's criticisms ...
  65. Analyzing Amgen's Price & Profitability Ratios in 2016 (AMGN)

    February 26, 2016
    Learn about Amgen's price ratios and profitability ratios and discover why it has one of the highest profit margins in the ...
  66. Are These the Top Biotech Stocks of 2016?

    January 19, 2016
    These three biotech stocks are likely hold up better than their peers in 2016.
  67. The Top 10 Healthcare Stocks for 2016 (ABT, AGN)

    January 6, 2016
    Learn about the top 10 health care stocks expected to grow in 2016, with brief insights into each company's growth potential ...
  68. The Top 4 Dividend Paying Biotechnology Stocks for 2016 (AMGN, ...

    January 5, 2016
    Discover the top four dividend-bearing biotech stocks for 2016, including one undervalued stock trading at bargain-basement ...
  69. The Top 5 Large Cap Biotechnology Stocks for 2016 (AMGN, BIIB)

    January 5, 2016
    Discover the top five biotechnology stocks for 2016. Learn each company's main revenue drivers and what factors cause their ...
  70. The Top 3 Biotechnology Stocks for 2016 (AMGN, VRX)

    December 30, 2015
    Find out more about the top three biotechnology stocks to consider in 2016, and learn about their characteristics and why ...
  71. 3 Biotech Blue-Chip Companies to Keep an Eye On (AMGN, BIIB)

    December 23, 2015
    Discover three blue-chip biotech stocks you should keep your eye on in 2016. Despite recent struggles in the industry, these ...
  72. The World's Top 10 Biotechnology Companies (JNJ, ROG.VX)

    December 22, 2015
    Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational ...
  73. The Top 5 Dividend Paying Healthcare Stocks for 2016 (JNJ, PFE)

    December 8, 2015
    Discover the top five dividend health care stocks for 2016, including two pharmaceutical giants and two newer dividend stocks ...
  74. Why Biotech Affimed N.V. Should Be On Your Radar (JUNO, AFMD)

    December 8, 2015
    In the world of developmental biotech, picking the correct early stage companies can potentially make investors a fortune.
  75. If You Had Invested Right After Amgen's IPO (AMGN)

    November 30, 2015
    Discover how $1,000 invested in Amgen during its initial public offering (IPO), without reinvesting dividends, would be worth ...
  76. Amgen to Acquire Dezima Pharma for $1.55 Billion (AMGN)

    September 17, 2015
    Amgen (NASDAQ: AMGN) is placing a bet on a promising new medication. The company announced it has agreed to acquire Netherlands-based ...
  77. Key Financial Ratios to Analyze Biotech Companies (AMGN, GILD)

    August 20, 2015
    Explore the rapidly growing biotechnology industry, and learn some of the key financial ratios investors use to analyze companies ...
  78. Amgen Dazzles With a Duo of Fresh Data (AMGN)

    June 23, 2015
    Sometimes it appears as if a biotech stock can do no wrong, and for shareholders of biotech behemoth Amgen (NASDAQ: AMGN), ...
  79. Better Dividend Stock: Amgen or Gilead Sciences? (AMGN, GILD)

    June 19, 2015
    Dividend investors don't have very many investing options in the high-flying biotechnology industry, but of those choices, Amgen ...
  80. Is Amgen About to Enter a Battle Over Billions? (AMGN, REGN)

    June 15, 2015
    The Food and Drug Administration's key advisory committee has given the thumbs-up to two new drugs belonging to an entirely ...
  81. This Trial Could Be Worth Billions to Amgen (AMGN)

    June 10, 2015
    Amgen (NASDAQ: AMGN) will soon know whether European and U.S. regulators will give it the go-ahead to begin marketing its ...
  82. Is This Johnson & Johnson's Next Blockbuster? (JNJ, AMGN)

    June 10, 2015
    Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) may not be associated with high-growth biotech companies, but ...
  83. This Key Amgen Drug Is Setting a Precedent (AMGN, NVS)

    June 8, 2015
    Biotech blue-chip stock Amgen (NASDAQ: AMGN) has practically had its way with Wall Street over the last five years. While ...
  84. Amgen Takes a Hit, Shelves Potential Blockbuster (AMGN, AZN)

    May 29, 2015
    Amgen's (NASDAQ: AMGN) investors learned this past week that the company is walking away from its deal with AstraZeneca (NYSE: ...
  85. Amgen Gets 1 Step Closer to Another Blockbuster (AMGN, REGN)

    May 26, 2015
    A key European advisory committee has just thrown its support behind approval for Amgen's (NASDAQ: AMGN) Repatha, a new ...
  86. Amgen's Late-Stage Pipeline Clears Another Hurdle (AMGN)

    May 20, 2015
    The 2000s were practically a lost time for Amgen (NASDAQ: AMGN) investors, with the company producing predominantly low-to-mid ...
  87. 5 Things Amgen's Management Wants You to Know (AMGN)

    May 11, 2015
    With its share price already having tripled over the trailing four-year period, Amgen (NASDAQ: AMGN) delivered more solid ...
  88. A Quick Guide To Healthcare ETFs

    May 8, 2015
    The healthcare industry offers a broad variety of sector ETFs but it’s difficult to avoid exposure to pharmaceuticals and ...
  89. Amgen Earnings Preview: 5 Questions to Ask (AMGN)

    April 16, 2015
    In the biotechnology sector, few companies are more synonymous with innovation than Amgen (NASDAQ: AMGN). Throughout the ...
  90. Amgen's Most Surprising Success Is Its Dividend (AMGN)

    April 9, 2015
    As recently as four years ago, few dividend investors would ever have expected to see big payouts from the biotechnology ...
  91. Will This EU Approval Move the Needle for Amgen? (AMGN)

    April 6, 2015
    European regulators have announced that Amgen's (NASDAQ: AMGN) long-standing colorectal cancer drug Vectibix is OK for use ...
  92. Risks and Rewards of Biotech Companies

    April 1, 2015
    We look at the risks and rewards of investing in biotech companies.
  93. Amgen Hopes Kyprolis Can Become a Blockbuster (AMGN)

    April 1, 2015
    When Amgen (NASDAQ: AMGN) handed over $9.7 billion to acquire Onyx Pharmaceuticals in 2013, some investors worried that ...
  94. Amgen's Dividend Could Double in 5 Years (AMGN)

    March 30, 2015
    Amgen's (NASDAQ: AMGN) dividend yield of 1.9% may not look very enticing to investors looking for income today. But a close ...
  95. Why These Could Be 2015's 10 Best Biotech Stocks

    March 25, 2015
    A quick look at a 10 biotech companies that are poised to deliver for shareholders in 2015.
  96. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  97. How Amgen Makes Billions On Just A Few Drugs

    November 5, 2014
    Amgen produces relatively few drugs, but that's doesn't mean it's any less essential or profitable. Here's a look at the ...
  98. Who are Amgen Inc.'s (AMGN) main competitors?

    August 27, 2014
    Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with.
  99. 4 Large-Cap Healthcare Stocks To Watch

    August 18, 2014
    Healthcare continues to a be a hot sector. Here are four pharma stocks to keep an eye on for entry points.
  100. Interested In Healthcare Stocks? Look At This ETF

    July 3, 2014
    Healthcare companies seem to be poised to make a move higher over the months ahead. Here's an ETF that should be helpful ...
  • Showing 1-100 of 103 items
  • 1
  • 2
  • >>